SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $19.35 and last traded at $18.85, with a volume of 110178 shares traded. The stock had previously closed at $18.49.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on SIBN shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th.
Get Our Latest Stock Analysis on SIBN
SI-BONE Stock Performance
The stock has a market cap of $843.35 million, a price-to-earnings ratio of -21.51 and a beta of 0.82. The firm's 50-day moving average is $14.83 and its two-hundred day moving average is $15.03. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.
SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. As a group, sell-side analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Insider Activity
In related news, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Anshul Maheshwari sold 4,937 shares of the stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total value of $83,929.00. Following the completion of the transaction, the chief financial officer now owns 265,356 shares of the company's stock, valued at $4,511,052. The trade was a 1.83% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,153 shares of company stock worth $935,040. Corporate insiders own 4.00% of the company's stock.
Institutional Investors Weigh In On SI-BONE
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new stake in SI-BONE in the first quarter worth $34,000. Virtus Fund Advisers LLC acquired a new position in shares of SI-BONE in the 4th quarter worth approximately $40,000. Mainstream Capital Management LLC acquired a new stake in shares of SI-BONE during the 4th quarter valued at $53,000. GAMMA Investing LLC lifted its holdings in shares of SI-BONE by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new position in shares of SI-BONE in the first quarter worth approximately $58,000. Hedge funds and other institutional investors own 98.11% of the company's stock.
About SI-BONE
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Articles
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
